Solventum Co. (NYSE:SOLV) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. boosted its holdings in shares of Solventum Co. (NYSE:SOLV - Free Report) by 0.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,266,893 shares of the company's stock after acquiring an additional 75,631 shares during the quarter. Vanguard Group Inc. owned about 9.42% of Solventum worth $1,074,591,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. State Street Corp raised its holdings in Solventum by 3.1% in the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company's stock valued at $425,818,000 after buying an additional 185,938 shares during the period. Geode Capital Management LLC increased its position in shares of Solventum by 4.0% during the third quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company's stock valued at $232,608,000 after acquiring an additional 128,317 shares during the last quarter. Hotchkis & Wiley Capital Management LLC purchased a new stake in shares of Solventum in the 3rd quarter valued at approximately $125,488,000. Boston Partners acquired a new position in shares of Solventum in the 4th quarter worth approximately $110,378,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Solventum by 0.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,053,771 shares of the company's stock worth $73,469,000 after purchasing an additional 3,745 shares during the period.

Solventum Stock Up 1.3 %

Shares of Solventum stock traded up $0.96 on Wednesday, reaching $77.30. 360,857 shares of the company were exchanged, compared to its average volume of 1,420,624. The stock's 50 day moving average price is $75.60 and its 200-day moving average price is $71.97. The company has a market cap of $13.37 billion and a P/E ratio of 28.06. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $85.92. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Analyst Ratings Changes

A number of research firms have commented on SOLV. Mizuho upped their price target on Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a research note on Monday, March 3rd. Piper Sandler increased their target price on Solventum from $75.00 to $84.00 and gave the stock a "neutral" rating in a research note on Friday, February 28th. Wells Fargo & Company raised their target price on Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a report on Friday, February 28th. Bank of America boosted their price target on shares of Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group raised their price objective on shares of Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a research note on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat.com, Solventum currently has an average rating of "Hold" and a consensus target price of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.